The place of S-ketamine in fibromyalgia treatment (ESKEFIB): study protocol for a prospective, single-center, double-blind, randomized, parallel-group, dose-escalation controlled trial
Abstract Background Fibromyalgia is a chronic multidimensional pain disease with no curative treatment currently available. Its management relies on a multimodal approach involving pharmacologic and non-pharmacologic elements. Because a suggested factor in its etiology is a central sensitization phe...
Guardado en:
Autores principales: | Zuzana Javorcikova, Michel Dangoisse, Stéphane Nikis, Jean-Paul Lechat, Aline Gillain, Jean-François Fils, Philippe Van der Linden |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/569b0e77782f454b8c7756c330a5a05b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
DNA Methylation Changes in Fibromyalgia Suggest the Role of the Immune-Inflammatory Response and Central Sensitization
por: Maria Carla Gerra, et al.
Publicado: (2021) -
Encefalitis autoinmunes: criterios diagnósticos y pautas terapéuticas
por: Collao-Parra,Juan Pablo, et al.
Publicado: (2018) -
Concentration of cytokines in patients with osteoarthritis of the knee and fibromyalgia
por: Imamura M, et al.
Publicado: (2014) -
Case Report: Unexpected Remission From Extreme and Enduring Bulimia Nervosa With Repeated Ketamine Assisted Psychotherapy
por: Anya Ragnhildstveit, et al.
Publicado: (2021) -
IMPACT OF FIBROMYALGIA ON DAS-28 SCORE IN RHEUMATOID ARTHRITIS
por: Ata Ur Rehman, et al.
Publicado: (2018)